Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness

Barbeau, 1975, Potentiation of levodopa effect by intravenous-l-prolyl-l-leucyl-glycine amide in man, Lancet, 2, 683, 10.1016/S0140-6736(75)90778-3 Ehrensing, 1974, Melanocyte-stimulating hormone release inhibiting hormone as an anti-depressant: A pilot study, Arch Gen Psychiatry, 30, 63, 10.1001/archpsyc.1974.01760070047007 Ehrensing, 1978, Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-1) in depression, Am J Psychiatry, 135, 562, 10.1176/ajp.135.5.562 Ehrensing, 1980, Effects of MIF-1 and TRH on the brain, 155 Ehrensing, 1982, MIF-1 and regulation of the hypothalamic-pituitary-adrenocortical system in depression, 299 Fischer, 1974, Effect of melanocyte-stimulating hormone release inhibiting factor (MIF) in Parkinson's syndrome, Eur Neurol, 12, 360, 10.1159/000114633 Kastin, 1972, Preliminary clinical studies with l-prolyl-l-leucyl-glycine amide in Parkinson's disease, Can Med Assoc J, 107, 1079 Levy, 1982, Rapid antidepressant activity of melanocyte inhibiting factor: A clinical trial, Biol Psychiatry, 17, 259 Plotnikoff, 1971, DOPA potentiation by a hypothalamic factor MSH-release inhibiting hormone (MIF), Life Sci, 10, 1279, 10.1016/0024-3205(71)90326-2 Plotnikoff, 1972, Oxotremorine antagonism by a hypothalamic hormone, melanocyte stimulating hormone release-inhibiting factor, MIF, 140, 811 Plotnikoff, 1973, Deserpidine antagonism by a tripeptide, l-prolyl-l-leucylglycinamide, Neuroendocrinology, 11, 67, 10.1159/000122119 Plotnikoff, 1974, DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucyl-glycinamide, Neuroendocrinology, 14, 271, 10.1159/000122270 Spitzer, 1978, Research Diagnostic Criteria for a Selected Group of Functional Disorders Winer, 1971, Statistical Principles in Experimental Design, 529